Leerink Partnrs Has Strong Forecast for Nkarta Q1 Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Equities research analysts at Leerink Partnrs upped their Q1 2025 earnings estimates for shares of Nkarta in a report issued on Wednesday, March 26th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($0.46) per share for the quarter, up from their previous estimate of ($0.51). The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta’s Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.44) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.66) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at ($1.34) EPS.

NKTX has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Nkarta in a research report on Thursday. Stifel Nicolaus dropped their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Nkarta in a research note on Thursday. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $14.86.

Nkarta Trading Up 1.5 %

Shares of NASDAQ NKTX opened at $2.00 on Monday. Nkarta has a 12-month low of $1.31 and a 12-month high of $11.84. The company has a market cap of $141.92 million, a price-to-earnings ratio of -1.06 and a beta of 0.90. The stock’s 50 day simple moving average is $1.99 and its 200 day simple moving average is $2.82.

Nkarta (NASDAQ:NKTX) last issued its earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06.

Insider Buying and Selling at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the sale, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. This represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.70% of the stock is owned by corporate insiders.

Institutional Trading of Nkarta

Hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. bought a new position in Nkarta during the fourth quarter valued at about $30,000. Sequoia Financial Advisors LLC acquired a new stake in Nkarta in the 4th quarter valued at about $31,000. Erste Asset Management GmbH acquired a new stake in Nkarta in the 3rd quarter valued at about $33,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Nkarta during the 4th quarter valued at about $37,000. Finally, ProShare Advisors LLC acquired a new position in shares of Nkarta in the 4th quarter worth approximately $45,000. Institutional investors own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.